NNNN - Anbio Biotechnology Price to Earnings Adjusted for Growth Rate
Anbio Biotechnology relies on a global supply network and an extensive range of diagnostic tests. The growth-weighted P/E reflects the business valuation trend, where the 0.00 mark captures this metric. Revenue is generated through the sale of analyzers and reagents to medical centers. High customer loyalty is ensured by a closed ecosystem of consumables and the possession of FDA/CE certifications.
Analytical breakdowns for Anbio Biotechnology (NNNN)
The PEG ratio measures market value efficiency relative to earnings growth rates, where a value below one signals that an asset is undervalued. The current valuation-to-earnings growth ratio for Anbio Biotechnology is 0.00, allowing for a comparison of the market multiple against the company's expansion in the rapid diagnostics segment and affordable test systems for immediate out-of-hospital disease detection.
